GE HealthCare Plunges 13% on Guidance Cut: Is It a Buy?

GE HealthCare (NASDAQ: GEHC) shares plunged 13% after the company cut its annual guidance. The stock currently trades at $59.49, far below the Wall Street consensus price target of $89.74, implying upside potential of about 50.8% if analysts are correct. GE HealthCare, the medical imaging and diagnostics business spun off from General Electric, generates approximately $20.6 billion in annual revenue across Advanced Imaging Solutions and Patient Care.

Recommendation Change

The article does not mention a specific analyst rating change, but it highlights the wide gap between the current price and the consensus target, which could attract value investors.

Analyst Rationale

Analysts believe GE HealthCare has strong fundamentals, including stable revenue from medical imaging and diagnostics. The guidance cut may be temporary due to supply chain issues or soft demand in certain markets, but long-term growth in healthcare supports the stock.

Context

The drop follows a period of weak performance. Other analysts have mixed views, but the consensus target remains high. The stock may be undervalued if conditions improve.

Conclusion

The guidance cut is a risk, but the large discount to the consensus target could offer an opportunity for long-term investors. Monitor upcoming earnings for signs of recovery.